Bristol Myers' $4.1B Turning Point acquisition gets clearance in US, Germany, set to close

Aug. 16, 2022 7:45 AM ETBristol-Myers Squibb Company (BMY)By: Ravikash, SA News Editor

word M and A made with wood building blocks, concept


  • Bristol Myers Squibb's (NYSE:BMY) $4.1B acquisition of Turning Point Therapeutics (NASDAQ:TPTX) received antitrust clearance in the U.S. and Germany.
  • New York-based Bristol Myers said that while the waiting period under a U.S. antitrust law expired, it also received merger control clearance from the Federal Cartel Office of Germany.
  • As of the expiration time, ~41.90M common shares were validly tendered, representing ~84% of the outstanding stock, BMY said in an Aug. 16 press release.
  • The companies expect the transaction to close on Aug. 17.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.